Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, ...

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platfo ...

Dr. Bryant Lin was diagnosed with stage IV lung cancer despite never smoking. (Norbert von der Groeben/Stanford University School of Medicine) Dr. Bryant Lin, a Stanford University School of ...

The ADC landscape has evolved significantly with treatments now approved for breast, lung, and hematologic ... fruitful in unlocking new pathways for ADCs, with the rise in collaborations between ...

Geneva, 25 November – In a world facing unprecedented levels of forced migration, climate-induced displacement, and deepening economic disparities, the need for safe, regular migration pathways has ...

During your time with Pathways to Medicine, you will participate in events and activities throughout Year 12 and 13. Every aspect of the programme is designed to help you make a strong and informed ...

The relatively new paradigm of 'rationally targeted' cancer drug therapies ... HER2, MET and ALK interface with common downstream signaling pathways and 'addiction switching' can occur, either ...

License includes Genprex's Reqorsa® Gene Therapy in Combination with ALK-Inhibitors for the Potential Treatment of ALK-Positive Lung ... pathways that cause replication and proliferation of ...

"Positive preclinical data indicate that REQORSA in combination with ALK inhibitors may provide benefit to patients with ALK-positive (ALK+) lung cancer. We are pleased to be able to protect this ...